Disc Medicine, Inc. (IRON) — SEC Filings
Disc Medicine, Inc. (IRON) — 47 SEC filings. Latest: 8-K (Dec 8, 2025). Includes 24 8-K, 6 10-Q, 6 SC 13G/A.
View Disc Medicine, Inc. on SEC EDGAR
Overview
Disc Medicine, Inc. (IRON) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Dec 8, 2025: Disc Medicine, Inc. filed an 8-K on December 8, 2025, reporting other events and financial statements/exhibits. The company, formerly known as Gemini Therapeutics, Inc. and FS Development Corp., is based in Watertown, MA, and operates in the pharmaceutical preparations industry. The filing date indi
Sentiment Summary
Across 47 filings, the sentiment breakdown is: 1 bullish, 2 bearish, 44 neutral. The dominant filing sentiment for Disc Medicine, Inc. is neutral.
Filing Type Overview
Disc Medicine, Inc. (IRON) has filed 24 8-K, 6 10-Q, 2 DEF 14A, 2 10-K, 6 SC 13G/A, 4 SC 13G, 3 SC 13D/A with the SEC between Jan 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (47)
Risk Profile
Risk Assessment: Of IRON's 35 recent filings, 2 were flagged as high-risk, 13 as medium-risk, and 20 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | N/A |
| Net Income | -$151.653M |
| EPS | -$1.77 |
| Debt-to-Equity | 0.05 |
| Cash Position | $140.664M |
| Operating Margin | N/A |
| Total Assets | $630.456M |
| Total Debt | $28.948M |
Key Executives
- William Savage
- Jonathan G. Drachman
- Jean Franchi
- John Quisel
- Len Blavatnik
- Rahul Khara
- Abigail P. Johnson
Industry Context
Disc Medicine operates in the highly competitive and capital-intensive biotechnology sector, focusing on developing therapeutics for hematologic diseases. The industry is characterized by long development cycles, significant R&D investment, and stringent regulatory hurdles. Success hinges on innovative science, effective clinical trial execution, and securing substantial funding to navigate the path to market approval.
Top Tags
operations (6) · disclosure (4) · corporate-filing (4) · financials (4) · 10-Q (4) · filing (4) · 8-K (3) · corporate-governance (3) · corporate-update (3) · amendment (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss (9 months ended Sep 30, 2025) | $151.653M | Increased from $79.900 million in 2024, indicating significant cash burn. |
| Research and Development Expenses (9 months ended Sep 30, 2025) | $124.416M | More than doubled from $71.874 million in 2024, reflecting increased pipeline investment. |
| Selling, General and Administrative Expenses (9 months ended Sep 30, 2025) | $44.636M | Increased from $23.296 million in 2024. |
| Cash and Cash Equivalents (as of Sep 30, 2025) | $140.664M | Decreased from $192.434 million at Dec 31, 2024. |
| Marketable Securities (as of Sep 30, 2025) | $475.256M | Increased from $297.447 million at Dec 31, 2024. |
| Proceeds from Common Stock Offering | $234.003M | Net of issuance costs, providing significant capital. |
| Proceeds from Pre-funded Warrants Offering | $9.386M | Net of issuance costs, contributing to capital. |
| Common Shares Outstanding (as of Sep 30, 2025) | 35,006,636 | Increased from 29,865,030 at Dec 31, 2024, indicating dilution. |
| Net Loss Per Share (Q3 2025) | $1.77 | Increased from $0.89 in Q3 2024. |
| SEC File Number | 001-39438 | Identifies the company's filing history with the SEC. |
| IRS Employer Identification No. | 85-1612845 | Company's tax identification number. |
| Net Loss | $49.8M | for the three months ended June 30, 2025, increased from $40.2M in Q2 2024 |
| Research and Development Expenses | $42.5M | for Q2 2025, up from $34.1M in Q2 2024 |
| General and Administrative Expenses | $10.1M | for Q2 2025, up from $8.0M in Q2 2024 |
| Cash and Cash Equivalents | $350.5M | as of June 30, 2025, down from $400.2M at December 31, 2024 |
Forward-Looking Statements
- {"claim":"FMR LLC will maintain a significant, passive stake in Disc Medicine, Inc. for the foreseeable future.","entity":"FMR LLC","targetDate":"2025-02-09","confidence":"high"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Disc Medicine, Inc. (IRON)?
Disc Medicine, Inc. has 47 recent SEC filings from Jan 2024 to Dec 2025, including 24 8-K, 6 10-Q, 6 SC 13G/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of IRON filings?
Across 47 filings, the sentiment breakdown is: 1 bullish, 2 bearish, 44 neutral. The dominant sentiment is neutral.
Where can I find Disc Medicine, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Disc Medicine, Inc. (IRON) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Disc Medicine, Inc.?
Key financial highlights from Disc Medicine, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for IRON?
The investment thesis for IRON includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Disc Medicine, Inc.?
Key executives identified across Disc Medicine, Inc.'s filings include William Savage, Jonathan G. Drachman, Jean Franchi, John Quisel, Len Blavatnik and 2 others.
What are the main risk factors for Disc Medicine, Inc. stock?
Of IRON's 35 assessed filings, 2 were flagged high-risk, 13 medium-risk, and 20 low-risk.
What are recent predictions and forward guidance from Disc Medicine, Inc.?
Recent forward-looking statements from Disc Medicine, Inc. include guidance on {"claim":"FMR LLC will maintain a significant, passive stake in Disc Medicine, Inc. for the foreseeable future.","entity.